Anbio Biotechnology
NNNN
$7.08
-$0.095-1.32%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.92M | 2.92M | 1.83M | 1.83M | 1.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.92M | 2.92M | 1.83M | 1.83M | 1.53M |
| Cost of Revenue | 969.50K | 969.50K | 1.04M | 1.04M | 631.30K |
| Gross Profit | 1.96M | 1.96M | 781.90K | 781.90K | 898.50K |
| SG&A Expenses | 92.30K | 92.30K | 444.70K | 444.70K | 187.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.13M | 1.13M | 1.56M | 1.56M | 819.20K |
| Operating Income | 1.80M | 1.80M | 269.80K | 269.80K | 710.60K |
| Income Before Tax | 1.80M | 1.80M | 366.50K | 366.50K | 760.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.80M | 1.80M | 366.50K | 366.50K | 760.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.80M | 1.80M | 366.50K | 366.50K | 760.30K |
| EBIT | 1.80M | 1.80M | 269.80K | 269.80K | 710.60K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.04 | 0.04 | 0.00 | 0.00 | 0.01 |
| Normalized Basic EPS | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.04 | 0.04 | 0.00 | 0.00 | 0.01 |
| Normalized Diluted EPS | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 42.29M | 42.29M | 142.29M | 142.29M | 142.29M |
| Average Diluted Shares Outstanding | 42.29M | 42.29M | 142.29M | 142.29M | 142.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
